![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif)
nedaplatin A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif)
Chemical structure name: | ![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif) | platinum, diammine(hydroxy-kappaO)acetato(2-)-kappaO)-, (SP-4-3)- | | ![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090115025524im_/http://www.cancer.gov/images/spacer.gif) |